ArticleDrug safety2026
Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdverse event reporting systems are an important source of safety signals for drug use in pregnancy, but their usefulness in the identification of potential drug-drug interactions (DDIs) remains unclear.
objectiveOur objective was to explore the reliability of signal detection for pharmacokinetic DDIs during pregnancy in adverse event reporting systems, focusing on potential interactions between antipsychotics (APs) or antidepressants (ADs) and drugs modifying cytochrome P450 (CYP450) activity, increasing the occurrence of gestational diabetes mellitus (GDM).
methodsReports related to the use of drugs during pregnancy were identified in VigiBase, the World Health Organization (WHO) global database of adverse event reports. Potential interacting drugs were selected based on WHO Drug Standardised Drug Groupings for CYP450 isoenzymes involved in the metabolic pathway of the AP or AD of interest. We conducted statistical interaction analysis using the omega disproportionality measure and including concomitant medication to identify potential DDIs, followed by a case series review for supporting evidence. Evaluation was subjective by author consensus.
resultsOf the 30 drug-drug-event combinations considered, statistical signals emerged for escitalopram, citalopram, and sertraline and the simultaneous use of CYP2D6 inhibitors with a higher relative reporting rate of GDM. However, case series review of reports did not support the existence of these DDIs because of uncertainties regarding the actual timing of medication use reported as concomitant.
conclusionStatistical signals of DDIs between ADs and potential interacting drugs during pregnancy were identified but not pursued further after case reviews. Uncertainty around medication use and event timing affected the reliability of the outcomes. These findings highlight the need to validate signals using detailed report data and stress the importance of accurate medication reporting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.